The Outcome of Haplo-Identical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report
Despite tremendous strides in the treatment of multiple myeloma (MM), the disease remains incurable and is defined by multiple series of responses and relapses. In the relapsed/refractory setting, outcomes for patients may be particularly discouraging. Moreover, patients with adverse cytogenetics and other high-risk features may experience particularly short progression-free survival (PFS) and inferior survival rates.[1]
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Firoozeh Sahebi, Laurent Garderet, Abraham S Kanate, Diderik-Jan Eikema, Nina Simone Knelange, Omar F D ávila Alvelo, Yener Koc, Didier Blaise, Qaiser Bashir, José M Moraleda, Peter Dreger, James F. Sanchez, Stefan Ciurea, Harry Schouten, Nirav N Shah, Source Type: research